In prostate cancer models, pharmacological inhibition of YAP1 was shown to induce phenotypic switching of CAFs from tumor‐promoting to tumor‐suppressive states, consequently enhancing the responsiveness of prostate tumors to immune checkpoint blockade (ICB) therapy [42]. Here, YAP1 is linked to prostate cancer.